Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 2;20(1):277.
doi: 10.1186/s12957-022-02742-8.

Prolonged postoperative length of stay may be a valuable marker for susceptibility to relapse beyond established risk factors in patients with stage III colon cancer

Affiliations

Prolonged postoperative length of stay may be a valuable marker for susceptibility to relapse beyond established risk factors in patients with stage III colon cancer

Frans Emland et al. World J Surg Oncol. .

Abstract

Background: Delay from surgery to adjuvant chemotherapy causes impaired survival among patients undergoing radical resection for stage III colon cancer, and the underlying mechanism for this is incompletely clarified. It is established that prolonged postoperative hospital length of stay (LOS) is associated with delayed initiation of the adjuvant treatment driving the assumption that prolonged LOS is prognostically unfavorable due to this fact and case mix factors. We hypothesize that prolonged LOS after surgery is a valuable marker for susceptibility to relapse that is not detected in established prognostic factors and, alone, associated with a shorter disease-free survival (DFS).

Materials and methods: A total of 690 consecutive patients undergoing elective radical resection for stage III colon cancer in 2000-2015 were identified in a prospective detailed facility database. Univariate and multivariate analyses were performed using Cox proportional hazards model in the evaluation of LOS as an independent prognostic factor.

Results: Short postoperative LOS, low comorbidity, and few complications were associated with longer DFS (p < 0.01). Fewer patients in the short and intermediate LOS groups had a relapse in their disease (28% and 33%, respectively), compared to the patients with longer LOS (40%, p < 0.05). LOS was a prognostic factor for DFS in the unadjusted univariate model (HR 1.04 per unit change) and remained statistically significant in the adjusted multivariate analysis, with a HR of 1.03 per hospital day (p < 0.01).

Conclusions: Postoperative LOS independently correlates with the risk of recurrence and DFS, regardless of if adjuvant chemotherapy is given, along with the factors such as age, comorbidity, complications, and tumor features. We propose a further investigation into the causal mechanisms based on tumor and host biology linking LOS to DFS beyond established risk factors.

Keywords: Colonic neoplasm; Disease-free survival; Postoperative length of stay; Prognostic risk factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Disease-free survival among patients operated electively for stage III colon cancer between the years 2000–2015, in relation to length of stay, Clavien-Dindo, and age-adjusted Charlson Comorbidity Index
Fig. 2
Fig. 2
Disease-free survival among the three length of stay groups, presented with two survival plots: one cohort who received adjuvant chemotherapy and one who failed to receive adjuvant chemotherapy

References

    1. (WHO) WHO. International Agency for Research on Cancer (IARC) - Colon cancer 2020: World Health Organization; 2020 [updated December 2020]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/8-Colon-fact-sheet.pdf.
    1. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116. doi: 10.1200/JCO.2008.20.6771. - DOI - PubMed
    1. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2020;31:1291–1305. doi: 10.1016/j.annonc.2020.06.022. - DOI - PubMed
    1. RCC. Nationellt vårdprogram tjock- och ändtarmscancer: Regionala cancercentrum i samverkan 2020. [Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/tjock-och-andtarmscanc...].
    1. Kennedy RH, Francis EA, Wharton R, et al. Multicenter randomized controlled trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme: EnROL. J Clin Oncol. 2014;32:1804–1811. doi: 10.1200/JCO.2013.54.3694. - DOI - PubMed

LinkOut - more resources